Saskia Ingen-Housz-Oro

List of Publications by Year
in descending order

166 papers	3,681 citations	159585 30 h-index	168389 53 g-index
216 all docs	216 docs citations	216 times ranked	2997 citing authors

#	Article	IF	Citations
1	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet, The, 2017, 389, 2031-2040.	13.7	438
2	Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Caseâ€“Control Study. Journal of Investigative Dermatology, 2011, 131, 637-643.	0.7	248
3	Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response. Science Translational Medicine, 2013, 5, 175ra30.	12.4	200
4	Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. British Journal of Dermatology, 2013, 169, 1223-1232.	1.5	121
5	Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology, 2013, 168, 726-732.	1.5	100
6	Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. British Journal of Dermatology, 2013, 169, 1041-1048.	1.5	99
7	Bacteremia in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Medicine (United States), 2010, 89, 28-36.	1.0	80
8	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. JAMA Dermatology, 2014, 150, 535.	4.1	80
9	Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica, 2014, 99, 527-534.	3.5	73
10	Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. Journal of Investigative Dermatology, 2019, 139, 835-841.	0.7	69
11	Calculation of cutâ€œoff values based on the Autoimmune Bullous Skin Disorder Intensity Score () Tj ETQq1 1 0.784314 rgBT /Overlock for defining moderate, significant and extensive types of pemphigus. British Journal of Dermatology, 2016, 175, 142-149.	1.5	68
12	Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. British Journal of Dermatology, 2015, 172, 1547-1554.	1.5	58
13	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. Journal of Investigative Dermatology, 2019, 139, 31-37.	0.7	55
14	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroidâ€sparing effect. British Journal of Dermatology, 2020, 182, 1111-1119.	1.5	55
15	Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de) Tj ETQq1 1 0.784314 rgBT /Overlock	2.7	54
16	First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical Corticosteroids. JAMA Dermatology, 2015, 151, 200.	4.1	48
17	Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. British Journal of Dermatology, 2011, 165, 1337-1343.	1.5	47
18	Efficacy and Tolerance of Antiâ€“Tumor Necrosis Factor Î± Agents in Cutaneous Sarcoidosis. JAMA Dermatology, 2017, 153, 681.	4.1	46

#	Article	IF	Citations
19	Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. Oncologist, 2016, 21, 76-83.	3.7	42
20	Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. British Journal of Dermatology, 2017, 177, 212-222.	1.5	42
21	Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in aÂRetrospective Cohort of 174 Patientsâ€"Exposed/Unexposed and Propensity Score-Matched Analyses. Journal of Investigative Dermatology, 2018, 138, 1293-1300.	0.7	41
22	Clinical and histologic features of Mycoplasma pneumoniae â€"related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. Journal of the American Academy of Dermatology, 2018, 79, 110-117.	1.2	41
23	Drugâ€induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. British Journal of Clinical Pharmacology, 2019, 85, 570-579.	2.4	41
24	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. JAMA Dermatology, 2020, 156, 545.	4.1	40
25	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. British Journal of Dermatology, 2021, 184, 1059-1067.	1.5	39
26	Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. Frontiers in Immunology, 2018, 9, 1030.	4.8	36
27	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders. American Journal of Surgical Pathology, 2020, 44, 862-872.	3.7	36
28	IgG4-Related Skin Disease Successfully Treated by Thalidomide. JAMA Dermatology, 2013, 149, 742.	4.1	35
29	Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre. British Journal of Dermatology, 2015, 172, 1455-1457.	1.5	34
30	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2015, 151, 302.	4.1	31
31	Primary Cutaneous Follicle Center Lymphomas Expressing BCL2 Protein Frequently Harbor BCL2 Gene Break and May Present 1p36 Deletion. American Journal of Surgical Pathology, 2016, 40, 127-136.	3.7	31
32	Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 437-440.	2.4	30
33	Postâ€traumatic stress disorder in Stevensâ€"Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. British Journal of Dermatology, 2019, 180, 1206-1213.	1.5	29
34	Incidence of and mortality from epidermal necrolysis (Stevensâ€"Johnson syndrome/toxic epidermal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Dermatology, 2020, 182, 618-624.	1.5	29
35	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. Blood, 2020, 135, 1058-1061.	1.4	29
36	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, LegÂType. Journal of Investigative Dermatology, 2018, 138, 1982-1989.	0.7	27

#	Article	IF	Citations
37	Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2021, 157, 1182.	4.1	27
38	Dermatological emergencies: a comparative study of activity in 2000 and 2010. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 916-918.	2.4	26
39	Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. British Journal of Dermatology, 2015, 172, 400-405.	1.5	26
40	Healthâ€related quality of life and longâ€term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. British Journal of Dermatology, 2020, 182, 916-926.	1.5	24
41	Association Between Severe Acute Contact Dermatitis Due toNigella sativaOil and Epidermal Apoptosis. JAMA Dermatology, 2018, 154, 1062.	4.1	22
42	Supportive care in the acute phase of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphiâ€based consensus. British Journal of Dermatology, 2021, 185, 616-626.	1.5	22
43	Interventions for erythema multiforme: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 842-849.	2.4	20
44	The Value of BP230 Enzyme-Linked Immunosorbent Assay in the Diagnosis and Immunological Follow-Up of Bullous Pemphigoid. Dermatology, 2012, 224, 154-159.	2.1	19
45	SÃ©zary syndrome without erythroderma. Journal of the American Academy of Dermatology, 2015, 72, 1003-1009.e1.	1.2	19
46	Positive Direct Immunofluorescence Is of Better Value than ELISA-BP180 and ELISA-BP230 Values for the Prediction of Relapse after Treatment Cessation in Bullous Pemphigoid: A Retrospective Study of 97 Patients. Dermatology, 2015, 231, 50-55.	2.1	19
47	Tâ€cell papulosis associated with Bâ€cell malignancy: a distinctive clinicopathologic entity. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1469-1475.	2.4	19
48	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Advances, 2020, 4, 5203-5214.	5.2	18
49	Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study. Journal of the American Academy of Dermatology, 2022, 86, 494-497.	1.2	18
50	Management of Bullous Pemphigoid with Topical Steroids in the Clinical Practice of a Single Center: Outcome at 6 and 12 Months. Dermatology, 2011, 222, 176-179.	2.1	17
51	HIV-Related CD8+ Cutaneous Pseudolymphoma: Efficacy of Methotrexate. Dermatology, 2013, 226, 15-18.	2.1	16
52	Trends in mortality rates for Stevensâ€“Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. British Journal of Dermatology, 2020, 182, 247-248.	1.5	16
53	Rituximab, a new treatment for difficultâ€toâ€treat chronic erythema multiforme major? Five cases. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1140-1143.	2.4	15
54	Dermatological emergencies: evolution from 2008 to 2014 and perspectives. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 274-279.	2.4	15

#	Article	IF	Citations
55	Cutaneous lymphomas appearing during treatment with biologics: 44 cases from theÂFrench Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. British Journal of Dermatology, 2019, 181, 616-618.	1.5	15
56	Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. Journal of the American Academy of Dermatology, 2019, 80, 1453-1455.	1.2	14
57	Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement. Orphanet Journal of Rare Diseases, 2020, 15, 259.	2.7	14
58	Individualâ€•and hospitalâ€•level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012â€“2016. British Journal of Dermatology, 2020, 182, 900-906.	1.5	13
59	Crossâ€•reactivity in betaâ€•lactams after a nonâ€•immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 787-794.	2.4	12
60	Folliculotropic Tâ€•cell infiltrates associated with Bâ€•cell chronic lymphocytic leukaemia or <scp>MALT</scp> lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 77-85.	2.4	11
61	Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. British Journal of Dermatology, 2015, 173, 1015-1023.	1.5	11
62	Central nervous system involvement of primary cutaneous diffuse large Bâ€•cell lymphoma, leg type: 13 cases. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e498-e501.	2.4	11
63	The diagnosis is in the rings. BMJ: British Medical Journal, 2017, 359, j3817.	2.3	11
64	Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. European Journal of Dermatology, 2017, 27, 271-274.	0.6	11
65	Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: A retrospective observational cohort study of 98 cases. Journal of the American Academy of Dermatology, 2019, 81, 342-347.	1.2	11
66	Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Research, 2022, 32, 205-210.	1.2	11
67	Rituximabâ€•related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 976-978.	2.4	10
68	Primary cutaneous aggressive epidermotropic <scp>CD8</scp>+ Tâ€•cell lymphoma with <scp>KIR3DL2</scp> and <scp>NKp46</scp> expression in a human immunodeficiency virus carrier. Journal of Cutaneous Pathology, 2015, 42, 199-205.	1.3	10
69	Gastrointestinal involvement in Stevensâ€“Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. British Journal of Dermatology, 2019, 180, 1234-1235.	1.5	10
70	Chronic pain: a longâ€•term sequela of epidermal necrolysis (Stevensâ€“Johnson syndrome/toxic epidermal) Tj ETQq0 0 0 rgBT /Overlock of Dermatology and Venereology, 2021, 35, 188-194.	2.4	10
71	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. Seminars in Arthritis and Rheumatism, 2021, 51, 436-441.	3.4	10
72	Life-threatening skin reaction with Enfortumab Vedotin: Six cases. European Journal of Cancer, 2022, 167, 168-171.	2.8	10

#	Article	IF	Citations
73	Severe sequelae of erythema multiforme: three cases. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e34-e36.	2.4	9
74	Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae. British Journal of Dermatology, 2019, 181, 421-422.	1.5	9
75	Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. British Journal of Dermatology, 2020, 182, 355-363.	1.5	9
76	Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma. JAMA Dermatology, 2015, 151, 1030.	4.1	8
77	Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. JAMA Dermatology, 2018, 154, 487.	4.1	8
78	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to ethambutol. MÃ©decine Et Maladies Infectieuses, 2018, 48, 302-305.	5.0	8
79	Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 cases. Annales De Dermatologie Et De Venereologie, 2021, 148, 168-171.	1.0	8
80	International multicentre observational study to assess the efficacy and safety of a 0Â·5 mg kg â¯1 per day starting dose of oral corticosteroids to treat bullous pemphigoid. British Journal of Dermatology, 2021, , .	1.5	8
81	Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by<scp>d</scp>-penicillamine in Wilson disease. British Journal of Dermatology, 2014, 171, 1574-1576.	1.5	7
82	Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that â€˜toxicâ€™ epidermal necrolysis can be â€˜nonâ€toxicâ€™. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e360-e361.	2.4	7
83	A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices. British Journal of Dermatology, 2018, 179, 1009-1011.	1.5	7
84	Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing. British Journal of Dermatology, 2018, 179, 978-979.	1.5	7
85	Dark skin phototype is associated with more severe ocular complications of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology, 2019, 181, 212-213.	1.5	7
86	Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms. European Journal of Dermatology, 2021, 31, 372-380.	0.6	7
87	Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2051-2058.	2.4	7
88	Febrile ulceronecrotic Mucha Habermann disease mimicking aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: a diagnostic challenge. European Journal of Dermatology, 2018, 28, 834-835.	0.6	7
89	Bullous pemphigoid: Three main clusters defining 3 outcome profiles. Journal of the American Academy of Dermatology, 2022, 87, 359-365.	1.2	7
90	Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients. Pathology, 2022, 54, 729-737.	0.6	7

#	Article	IF	Citations
91	Primary cutaneous T-cell lymphoma presenting as mycosis fungoides with a T-/null-cell phenotype: report of two cases. British Journal of Dermatology, 2015, 172, 1637-1641.	1.5	6
92	Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases. British Journal of Dermatology, 2018, 178, e5-e6.	1.5	6
93	Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. British Journal of Dermatology, 2019, 180, 666-667.	1.5	6
94	Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. Clinical and Experimental Dermatology, 2021, 46, 1441-1451.	1.3	6
95	Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. Journal of the American Academy of Dermatology, 2020, 83, 1166-1170.	1.2	6
96	Extensive telangiectases of the scalp: atypical presentation of primary cutaneous follicle centre lymphoma. British Journal of Haematology, 2012, 158, 297-297.	2.5	5
97	Severe Cutaneous Adverse Reactions to Drugs: From Patients to the National Office for Compensation of Medical Accidents. Dermatology, 2014, 228, 338-343.	2.1	5
98	Dermatitis herpetiformis and bone mineral density: analysis of a French cohort of 53 patients. European Journal of Dermatology, 2017, 27, 353-358.	0.6	5
99	Treatment of mycosis fungoides and SÃ©zary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. British Journal of Dermatology, 2019, 180, 423-424.	1.5	5
100	Cutaneous tests and interest of iobitridol in nonâ€immediate hypersensitivity to contrast media: a case series of 43 patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e178-e180.	2.4	5
101	Patch tests in nonâ€immediate cutaneous adverse drug reactions: the importance of late readings on day 4. Contact Dermatitis, 2021, , .	1.4	5
102	Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme. JAMA Dermatology, 2021, 157, 1472.	4.1	5
103	Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a patient with SÃ©zary syndrome treated by methotrexate. British Journal of Dermatology, 2016, 175, 430-433.	1.5	4
104	Acute generalized exanthematous pustulosis and epidermal necrolysis differ in innate cytokine patterns. Clinical and Experimental Allergy, 2019, 49, 1258-1261.	2.9	4
105	Response to â€˜Cutaneous eruptions associated with haematological malignancies: the need for a unifying nomenclatureâ€™. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e193-e193.	2.4	4
106	Strong reactions to diltiazem patch tests: Plea for a low concentration. Contact Dermatitis, 2020, 83, 224-225.	1.4	4
107	Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases. Contact Dermatitis, 2021, 84, 280-282.	1.4	4
108	Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports. Therapie, 2021, , .	1.0	4

#	Article	IF	Citations
109	Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1569-1576.	2.4	4
110	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. Blood, 2021, 138, 790-790.	1.4	4
111	IgG4-Related Skin Diseaseâ€"Reply. JAMA Dermatology, 2013, 149, 1440.	4.1	3
112	Pemphigoid gestationis revealing a denial of pregnancy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1411-1413.	2.4	3
113	Stevens-Johnson Syndrome During Pregnancy. JAMA Dermatology, 2018, 154, 224.	4.1	3
114	Response to systemic therapies in granulomatous cheilitis: Retrospective multicenter series of 61 patients. Journal of the American Academy of Dermatology, 2022, 86, 667-669.	1.2	3
115	Lupus erythematosus and epidermal necrolysis: a case series of 16 patients. British Journal of Dermatology, 2022, 186, 372-374.	1.5	3
116	Adenovirus-induced Erythema Multiforme: Eye and Genital Mucosal Involvement is Specific, Whereas Oral and Cutaneous Involvement is Not. Acta Dermato-Venereologica, 2020, 100, adv00181.	1.3	3
117	Calcinosis cutis in epidermal necrolysis: role of caspofungin?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	3
118	Erythema multiforme associated with antiâ€plakin antibodies: a multicentric retrospective case series. Journal of the European Academy of Dermatology and Venereology, 0, , .	2.4	3
119	Dermatosurgery: Total Quality Management in a Dermatology Department. Dermatology, 2012, 225, 204-209.	2.1	2
120	Suspected Viral Maculopapular Eruptions: An Audit of Practice. Dermatology, 2013, 227, 72-77.	2.1	2
121	Nodules on a sternotomy scar. Lancet Infectious Diseases, The, 2015, 15, 986.	9.1	2
122	Primary cutaneous mucormycosis as a complication of erosive dermatitis: two cases. European Journal of Dermatology, 2018, 28, 227-229.	0.6	2
123	Lookalike and soundalike drugs: a potential cause of cutaneous adverse reactions to drugs. British Journal of Dermatology, 2019, 181, 626-627.	1.5	2
124	Iloprost: a potential alternative for skin graftâ€resistant hypertensive leg ulcer. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e726-e728.	2.4	2
125	Carrying out local care for epidermal necrolysis: survey of practices. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e155-e157.	2.4	2
126	Involvement of smallâ€diameter nerve fibres in longâ€term chronic pain after Stevensâ€"Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e218-e221.	2.4	2

#	Article	IF	Citations
127	Essential oils as potential triggers for bullous pemphigoid? A report of two patients. European Journal of Dermatology, 2021, 31, 92-93.	0.6	2
128	Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous Tâ€cell lymphoma: nine cases. British Journal of Dermatology, 2021, 185, 1061-1063.	1.5	2
129	Effect of expression of ICOS in cutaneous T-cell lymphoma and its targeting on killing of malignant cells.. Journal of Clinical Oncology, 2020, 38, e20040-e20040.	1.6	2
130	Real-life impact of immunologic tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study. Journal of the American Academy of Dermatology, 2022, 86, 1293-1300.	1.2	2
131	Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis. British Journal of Dermatology, 2022, 186, 1037-1039.	1.5	2
132	Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase. Pharmacoepidemiology and Drug Safety, 2022, 31, 434-441.	1.9	2
133	Cutaneous gamma delta <scp>Tâ€Cell</scp> lymphoma with indolent evolution: a series of five cases. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	2
134	Psychotherapeutic interventions for burns patients and the potential use with Stevens-Johnson syndrome and toxic epidermal necrolysis patients: A systematic integrative review. PLoS ONE, 2022, 17, e0270424.	2.5	2
135	Linear immunoglobulin A disease and vancomycin: letter in reply. British Journal of Dermatology, 2014, 171, 1602-1604.	1.5	1
136	Atypical psoriasis. BMJ, The, 2015, 351, h5510.	6.0	1
137	Selfâ€diagnosed drug allergies: the belief of patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e524-e526.	2.4	1
138	A polymorphous bullous dermatosis. Lancet Oncology, The, 2017, 18, e776.	10.7	1
139	Healthâ€related quality of life and longâ€term related conditions in survivors of epidermal necrolysis: a study of 57 patients. British Journal of Dermatology, 2020, 182, e145.	1.5	1
140	Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. British Journal of Dermatology, 2021, 184, 356-358.	1.5	1
141	Mycosis fongoÃ¯de et lymphomes T Ã©rythrodermiques. Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 40-47.	0.0	1
142	Prise en charge dâ€™un exanthÃ¨me maculo-papuleux. Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 114-117.	0.0	1
143	Pustulose exanthÃ©matique aiguÃ« gÃ©nÃ©ralisÃ©e (PEAG). Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 177-181.	0.0	1
144	Which patients present to dermatologic emergencies? A survey on 1561 patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e583-e585.	2.4	1

#	Article	IF	Citations
145	Nonuraemic calciphylaxis: A case series. Annales De Dermatologie Et De Venereologie, 2021, 148, 127-129.	1.0	1
146	Syphilis has no age limit. Age and Ageing, 2021, 50, 2270-2270.	1.6	1
147	Pityriasis lichenoides: a clinical and pathological case series of 49 patients with an emphasis on followâ€up. Clinical and Experimental Dermatology, 2021, 46, 1561-1566.	1.3	1
148	16S metagenomic assessment of the skin microbiota dynamic and possible association with the risk of infection in patients with epidermal necrolysis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e914-e917.	2.4	1
149	PD1 in SÃ©zary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?. European Journal of Cancer, 2021, 156, S14-S15.	2.8	1
150	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. European Journal of Cancer, 2021, 156, S23-S24.	2.8	1
151	Don't Judge a Book by its Cover. â€˜Steroid Acneâ€™: an unrecognized role of Malassezia and Demodex?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
152	High frequency of eosinophilia and viral reactivation in drug hypersensitivity in patients with severe acute respiratory syndrome coronavirus 2 infection. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
153	Axonal Guillainâ€Barrã© syndrome and toxic epidermal necrolysis: two cases. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
154	Cutaneous Tumor of the Arm Revealing a Sporadic Burkitt Lymphoma. Journal of the American Geriatrics Society, 2016, 64, 1141-1142.	2.6	0
155	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1344-1346.	3.8	0
156	Extensive cutaneous and muscular mucormycosis complicating insulin pump treatment. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e486-e489.	2.4	0
157	Dermatose Ã IgA linÃ©aires. Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 118-121.	0.0	0
158	Ã‰rythÃ¨me polymorphe. Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 578-578.	0.0	0
159	Dermatite herpÃ©tiforme. Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 319-321.	0.0	0
160	Intravenous immunoglobulins: an eye opener on the successful treatment of severe adultâ€onset paraproteinâ€associated xanthogranulomatosis. Clinical and Experimental Dermatology, 2021, 46, 1346-1348.	1.3	0
161	Lymphomes B cutanÃ©s primitifs indolentsÂ: lymphome B centrofolliculaire et lymphome B de la zone marginale. Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 589-589.	0.0	0
162	DÃ©faillance cutanÃ©e aiguÃ«Â: consÃ©quences et principes gÃ©nÃ©raux de prise en charge. Annales De Dermatologie Et De VÃ©nÃ©rÃ©ologie, FMC, 2021, 1, 583-588.	0.0	0

#	Article	IF	Citations
163	Urgences dermatologiques en rÃ©animation : infections nÃ©crosantes de la peau et des parties molles et toxidermies graves. Medecine Intensive Reanimation, 2018, 27, 461-474.	0.0	0
164	Republication deÂ: Traitement des toxidermies graves. Journal Europeen Des Urgences Et De Reanimation, 2018, 30, 161-171.	0.1	0
165	Quoi de neuf en dermatologie clinique?. Annales De Dermatologie Et De Venereologie, 2019, 146, 12S1-12S10.	1.0	0
166	Missed Diagnosis of Epilepsy-Associated Scald Burns: Two Cases Initially Diagnosed as Bullous Dermatosis. Journal of Burn Care and Research, 2021, 42, 569-572.	0.4	0